The drugmaker has paired up with Incyte and CytomyX in two separate deals.
The two-year collaboration leverages health content from Meredith Vieira's Lives project.
The drugmaker said JAK inhibitor GSK2586184 showed no effect in Phase II and has put an ulcerative colitis test on hold.
The company expects to return to growth in 2015 as it focuses on immunotherapy collaborations.
Ten pharma companies will share money and biomarker research under an NIH collaboration.
The two will explore cancer-attacking nanobodies.
The companies are changing the key compound.
The new deals seek out new strategies to address an expansive category.
The commericalization/development deal covers up to six anti-cancer assets, and gives OncoMed a 50/50 US partnership over the experimental monoclonal antibody demcizumab.
AstraZeneca and Roche strike antibiotic deals.
Monday's announcement builds on a stream of recent R&D relationships.
Despite a possible government standoff, exchanges are coming, as is a proffered rebrand; Amgen signs a university deal in China; Pakistan seeks to rein in pharma; digital marketing is on the rise, research shows
AbbVie and Galapagos go after cystic fibrosis; FDA's NME approval pace slows; government shutdown could slow ad-com votes; and a report shows privately insured patients had emptier pockets in 2012 than 2011
Complete Response letter slows Merck's suggamedex; AbbVie looks for next Humira; Roche drug gets breakthrough label; FDA effort to better track medical devices
Gilead's Striblid faces hurdle in Germany, Boehringer and Roche team up for companion diagnostic effort and Wisconsin hospital system says no to samples
BI cancer drug lands breakthrough therapy designation; Sanofi tallies two European MS drug approvals; GSK terminates testing for a Crohn's drug; and Teva joins cancer collaboration
FDA draft guidance for generic Advair hits GSK's stock; US looks into GSK's China conduct; Roche invests in cancer and hep. B research; Biogen inks a Parkinson's partnership; Forest names former B&L chief as CEO
Australia's price watchdogs are assessing the value of BMS cancer drug Yervoy; why a Phase II weight drug from Zafgen could open up the category; GSK halts a Crohn's trial; and Shire extends Santaris rare-disease collaboration
Sanofi may make OTC history; Celgene joins a new collaboration; and the US Task Force of Preventative Medicine wants to make lung cancer screening the norm
Amgen pays $50 million for a cardio collaboration, and Wockhardt gets locked out of the EU.
Astellas teams up with Cytokinetics for muscle weakness research; ADA says lifestyle changes don't protect diabetics' hearts; AJMC talks pharmacists as diabetes counselors; and AARP helps with healthcare reform education.
Sales fell more sharply during the quarter than execs expected, and Merck said it has put more Januvia-only reps behind its diabetes franchise.